Close Menu

Asuragen subsidiary Mirna Therapeutics this week unveiled preclinical data showing that one of its microRNA mimics inhibited tumor growth and metastases in a variety of animal models without toxicity.

These data, along with the publication last week of a report showing that therapeutic miRNA delivery could suppress tumorigenesis in a mouse model of liver cancer, suggest that miRNA replacement could be a safe and effective therapeutic strategy for cancer, Mirna CEO Matt Winkler told RNAi News this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Retraction Watch writes that a cancer researcher has had an eighth paper retracted.

Computational biologist James Taylor has died, according to Johns Hopkins University.

The Centers for Disease Control and Prevention is starting to test people for SARS-CoV-2 antibodies, according to the New York Times.

In PLOS this week: features of tumor-infiltrating immune cells, regulatory effects of SNPs associated with prostate cancer risk, and more.